Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 01 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Ivabradine Tablets in two dosages. The approval allows Zydus to manufacture the drug at its facility in Ahmedabad SEZ, India, which is indicated for heart failure treatment. Zydus was among the first applicants for this drug and may qualify for a period of generic exclusivity. The press release aims to inform investors and the exchange members about this significant regulatory milestone.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases